0
0
The Drugs Controller General of India (DCGI) has issued a safety advisory for both patients and healthcare professionals, urging them to discontinue the use of the widely-used antacid, Digene Gel. This advisory stems from safety concerns following a voluntary recall initiated by the pharmaceutical company Abbott.
In line with the DCGI’s directive, healthcare practitioners are advised to exercise caution when prescribing Digene Gel and to inform their patients to cease its usage. Furthermore, they are encouraged to promptly report any adverse drug reactions (ADRs) that may result from its consumption.
Consumers and patients are strongly recommended to stop using the product, particularly those batches manufactured at Abbott’s Goa facility. Additionally, wholesalers and distributors have been instructed to withdraw all affected batches, manufactured at the Goa facility and still within their active shelf life, from the distribution network.
In an advisory, state drug controllers have also been called upon to maintain strict oversight over the movement, sale, distribution, and stock of the aforementioned drug products in the market. They are authorized to collect samples from the market and take appropriate actions as per the provisions of the Drugs and Cosmetics Act and Rules.
